Last reviewed · How we verify

Salah Awad Alanazi — Portfolio Competitive Intelligence Brief

Salah Awad Alanazi pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ferulic Acid Ferulic Acid marketed Non-Standardized Chemical Allergen [EPC]

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 1 shared drug class
  2. City of Hope Medical Center · 1 shared drug class
  3. Ferring Pharmaceuticals · 1 shared drug class
  4. Novartis · 1 shared drug class
  5. University of Oklahoma · 1 shared drug class
  6. WU XI ZHONG ZHI WEI NA TECHNOLOGY CO., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Salah Awad Alanazi:

Cite this brief

Drug Landscape (2026). Salah Awad Alanazi — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/salah-awad-alanazi. Accessed 2026-05-18.

Related